← All trials
NCT03259698
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 358
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- University of TorontoOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- CIHR Canadian HIV Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.